PSI CRO opens in Taiwan, looks to Hong Kong for 2018

19-Sep-2017 - Last updated on 20-Sep-2017 at 15:56 GMT

(Image: lovelyday12)

Related tags Asia pacific Ulcerative colitis

The Switzerland-headquartered contract research organization (CRO) has opened offices in Taiwan following a string of investments in the Asia Pacific region.

The new office will be listed as Taiwan PSI Health Development Co. Ltd.

According to the CRO, its expansion has been driven by demand in oncology, infections, IBD (ulcerative colitis, Crohn’s Disease), and other therapeutic areas.

“Taiwan is an important contributor to global clinical trials,” said Olga Alfonsova, head of corporate development at PSI CRO.

“That’s why PSI has opened an office in Taipei and will continue to grow within the country to access the most prominent investigative sites in the areas of oncology, infections, inflammatory bowel diseases, neurology and other therapeutic areas,” she told us.

The Switzerland-based company is “perfectly on track” with its plans to expand into Asia Pacific, said Alfonsova. So far this year the company has established offices in Sydney, Australia; Seoul, South Korea, and Taipei; Taiwan.

Alfonsova explained Hong Kong will be next at the beginning of 2018.

“The expansion into Asia Pacific region is well-paced and allows global sponsors access to Asian populations across a variety of therapeutic indications,” she added.